Thursday, November 12, 2026

Goldman Sachs Forecasts 7-Point ROE Decline for Big Tech as AI Capex Outpaces Revenue

Goldman Sachs forecast a 7 percentage point average decline in Big Tech return on equity over the next year, warning AI infrastructure spending is outpacing revenue generation. The June 12 report targets Microsoft, Alphabet, Meta, Amazon, and Apple, citing an 18-to-24-month lag between capital investment and revenue recognition. The S&P 500's 9% year-to-date return reflects market valuations that may not yet price in the compression ahead.

LM Salvado

June 17, 2026

Goldman Sachs Forecasts 7-Point ROE Decline for Big Tech as AI Capex Outpaces Revenue
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Goldman Sachs forecast a 7 percentage point average decline in Big Tech return on equity over the next year, warning that AI infrastructure spending is outpacing revenue generation.1

The June 12 report centers on Microsoft, Alphabet, Meta, Amazon, and Apple — the five largest AI infrastructure investors.1 These companies dominate S&P 500 weighting and collectively set the tone for market earnings expectations.

AI hardware and infrastructure investment cycles typically lag revenue generation by 18 to 24 months.1 That structural gap means capital expenditure compresses margins before monetization begins to offset the cost. The bigger the upfront spending, the longer the drag.

Return on equity measures how efficiently a company converts shareholder equity into profit. A 7-point compression across five of the most profitable businesses in the index would represent a notable deterioration in capital efficiency — one that current valuations may not reflect.

The S&P 500 returned 9% year-to-date on the back of earnings growth.1 Market pricing assumes continued profitability at the largest tech firms. Goldman's forecast challenges that assumption directly.

The counterargument rests on timing. AI proponents argue monetization will outpace prior infrastructure cycles. Cloud computing in the 2010s took years to turn margin-accretive; the case is that AI services — inference, APIs, enterprise tools — will close that gap faster.

Confirming the Goldman thesis requires tracking quarterly ROE across all five companies over four consecutive quarters. A verified average decline of 5 to 9 percentage points would validate the projection.1

The implications reach beyond individual earnings. ROE compression at this scale would ripple through index returns, analyst estimates, and institutional capital allocation. AI infrastructure spending shows no sign of slowing — making the revenue side of that equation the critical variable to watch over the next 12 months.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com